Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinical and laboratory parameters of the limited-1 and limited-2 subgroups

From: Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature

Clinical feature Limited 1 (n = 10) Limited 2 (n = 5)
MRSS, median (range) 5.5 (3–10) 6 (5 − 7)
Disease duration from first non-Raynaud’s symptom, median (range) years 16 (4–40) 6 (2–28)
ANA primary pattern, N (%) patients Homogenous 3 (30) 1 (20)
Speckled 1 (10) 1 (20)
Centromere 5 (50) 1 (20)
Nucleolar 0 1 (20)
SSc-specific antibodies Scl-70 3 (30) 1 (10)
RNA pol III 0 0
Vasculopathy, N (%) patients Digital ulcers 4 (40) 2 (40)
PAH 0 0
Renal crisis 0 0
Interstitial lung disease, N (%) 2 (20) 2 (40)
Inflammatory arthritis, N (%) 3 (30) 0
Vascular therapies, N (%) patients ARB 8 (80) 2 (40)
Ca channel antagonist 2 (20) 2 (40)
Iloprost 3 (30) 1 (20)
PDE5 inhibitor 1 (10) 2 (40)
Immunosuppressive therapies, N (%) patients PDN 2 (20) 2 (40)
MMF 2 (20) 1 (20)
MTX 2 (20) 0
AZA 1 (10) 0
HCQ 2 (20) 1 (20)
  1. ANA antinuclear antibodies, SSc systemic sclerosis, MRSS modified Rodnan skin score, PAH pulmonary arterial hypertension, ARB angiotensin receptor blocker, PDE cGMP-regulated phosphodiesterase, MTX methotrexate, HCQ hydroxychloroquine, PDN prednisolone, AZA azathioprine